CriticalAntiretroviral, HIV protease inhibitor×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
CYP3A4 inhibition by atazanavir raises pimozide – torsades de pointes.
Symptoms
QT prolongation, syncope.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- EMA: Reyataz (atazanavir) SmPC (2024)– EMA EPAR Reyataz